GAITHERSBURG, Md., Sept. 5,
2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:
YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and
delivering new generations of vaccines and therapeutic biologics
for infectious diseases and cancer, today announced that it will
participate in in Citi's 18th Annual Biopharma Conference from
Tuesday, September 5 to Thursday, September 7, 2023.
Dr. David Shao, YS Biopharma
Chief Executive Officer, and other members of the Company's
management team will attend and will be available for one-on-one
and small group meetings.
For more information on the conference, please contact your
conference representative. Meeting requests may also be emailed to
YSBiopharma.IR@icrinc.com.
About YS Biopharma
YS Biopharma is a global
biopharmaceutical company dedicated to discovering, developing,
manufacturing, and delivering new generations of vaccines and
therapeutic biologics for infectious diseases and cancer. It has
developed a proprietary PIKA® immunomodulating
technology platform and a new generation of preventive and
therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B,
Influenza, Shingles, and other virus infections.
YS Biopharma operates in China, the United
States, Singapore, and the Philippines, and is led by a management team
that combines rich local expertise and global experience in the
biopharmaceutical industry. For more information, please
visit investor.ysbiopharm.com.
Investor Relations Contacts
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-to-participate-in-participate-in-citis-18th-annual-biopharma-conference-301917440.html
SOURCE YS Biopharma Co., Ltd.